COVID-19 Frequently Asked Questions
Increasing Production to Meet Demand
Hillrom’s business operations continue as global demand for several critical products has grown substantially. Hillrom is working to significantly ramp up production of these products with the goal of at least doubling capacity where possible in the following areas:
- ICU and med-surg unit smart beds, including the company’s Progressa® ICU bed, Centrella® Smart+ bed, and, for international markets, the Hillrom™ 900 and Hillrom 900 Accella™ beds.
- Patient monitoring and diagnostics, including the company’s Connex® and Spot Vital Signs® monitors as well as physical assessment tools and consumables, including thermometry, probe covers and blood pressure devices and cuffs.
- Respiratory health, especially Life2000®, a non-invasive ventilator currently approved in the U.S. that is portable, lightweight and ideal for treating patients with mild to moderate respiratory distress across various acute care settings, including the emergency department, med-surg and post-ventilator weaning support. Expanded use of non-invasive ventilation can free up capacity for invasive ventilators for the most serious COVID-19 patients. Hillrom is working to increase its production capacity of Life2000 ventilators five-fold on an annualized basis.
We have a dedicated team executing business continuity plans by product line. We are monitoring product inventory, raw materials and component needs daily to meet customer demand for most of our products around the world. Hillrom’s business operations continue with no material interruption, and we are actively managing supply risks. Hillrom carefully follows WHO and U.S. CDC directives, as well as individual country guidance regarding transportation and shipping availability.